- Home
- MYGN vs FCBC Comparison
MYGN vs FCBC Comparison
Compare MYGN & FCBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- FCBC
- Stock Information
- Founded
- MYGN 1991
- FCBC 1874
- Country
- MYGN United States
- FCBC United States
- Employees
- MYGN N/A
- FCBC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- FCBC Major Banks
- Sector
- MYGN Health Care
- FCBC Finance
- Exchange
- MYGN Nasdaq
- FCBC Nasdaq
- Market Cap
- MYGN 625.5M
- FCBC 590.1M
- IPO Year
- MYGN 1995
- FCBC 1992
- Fundamental
- Price
- MYGN $6.65
- FCBC $32.72
- Analyst Decision
- MYGN Hold
- FCBC
- Analyst Count
- MYGN 14
- FCBC 0
- Target Price
- MYGN $13.23
- FCBC N/A
- AVG Volume (30 Days)
- MYGN 1.1M
- FCBC 35.5K
- Earning Date
- MYGN 11-03-2025
- FCBC 10-28-2025
- Dividend Yield
- MYGN N/A
- FCBC 3.77%
- EPS Growth
- MYGN N/A
- FCBC N/A
- EPS
- MYGN N/A
- FCBC 2.68
- Revenue
- MYGN $825,300,000.00
- FCBC $164,262,000.00
- Revenue This Year
- MYGN $0.06
- FCBC $2.27
- Revenue Next Year
- MYGN $5.68
- FCBC $11.13
- P/E Ratio
- MYGN N/A
- FCBC $12.26
- Revenue Growth
- MYGN 0.21
- FCBC 0.67
- 52 Week Low
- MYGN $3.76
- FCBC $31.75
- 52 Week High
- MYGN $16.83
- FCBC $48.34
- Technical
- Relative Strength Index (RSI)
- MYGN 41.25
- FCBC 41.21
- Support Level
- MYGN $6.25
- FCBC $31.94
- Resistance Level
- MYGN $6.83
- FCBC $33.67
- Average True Range (ATR)
- MYGN 0.43
- FCBC 0.80
- MACD
- MYGN -0.09
- FCBC 0.09
- Stochastic Oscillator
- MYGN 23.90
- FCBC 23.12
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.